EUVIMEDEUVIMED entdecken
Crossref

Vitamin D receptor gene polymorphisms, bioavailable 25-hydroxyvitamin D, and hepatocellular carcinoma survival

Jing Shu iD, Mingjie Zhang, Xiaocong Dong, Jingan Long, Yunshan Li, Peishan Tan, Tongtong He iD, Edward L Giovannucci, Xuehong Zhang iD, Zhongguo Zhou, Yanjun Xu, Xiaojun Xu und 6 weitere

JNCI: Journal of the National Cancer Institute · 2024

DOI: 10.1093/jnci/djae116 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JNCI: Journal of the National Cancer Institute, 2024. Verfasst von Jing Shu und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nutrition, Guangdong Provincial Key Laboratory of Food, Nutrition, and Health, School of Public Health, Sun Yat-sen University, Guangzh…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Receptors, Calcitriol, Liver Neoplasms, Vitamin D. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Guangdong Province, Science and Technology Program of Guangzhou.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Little is known about the role of vitamin D receptor polymorphisms and their interaction with vitamin D status in hepatocellular carcinoma (HCC) prognosis.

Methods

We evaluated the association of TaqI, BsmI, Cdx-2, and ApaI polymorphisms, individually and in combination, with liver cancer-specific (LCSS) and overall survival (OS) among 967 patients with newly diagnosed HCC. Subsequently, we examined whether these polymorphisms modified the association between serum bioavailable 25-hydroxyvitamin D (25OHD) concentrations and survival. Cox proportional hazard models were used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs).

Results

During a median follow-up of 1017 days, 393 deaths occurred, with 360 attributed to HCC. Having TaqI G allele (HRper allele = 1.30, 95% CI = 1.08 to 1.57) or BsmI T allele (HRper allele = 1.41, 95% CI = 1.01 to 1.99) was associated with worse LCSS. Carrying increasing numbers of protective alleles was associated with superior LCSS (HR6-8 vs 0-3 = 0.52, 95% CI = 0.34 to 0.80). The inverse association of bioavailable 25OHD with LCSS was statistically significant only in patients with TaqI AA (HRQuartile 4 vs Quartile 1 = 0.63, 95% CI = 0.44 to 0.92), BsmI CC (HRQuartile 4 vs Quartile 1 = 0.62, 95% CI = 0.44 to 0.88), and 6 to 8 protective alleles (HRQuartile 4 vs Quartile 1 = 0.45, 95% CI = 0.23 to 0.87). Similar associations were observed for OS.

Conclusions

Patients carrying wild-type TaqI, BsmI, or more protective alleles had improved survival and might benefit from optimizing bioavailable 25OHD status.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularReceptors, CalcitriolLiver NeoplasmsVitamin DHumansMaleFemaleMiddle AgedAgedProportional Hazards ModelsPrognosisAllelesAdultPolymorphism, Single NucleotidePolymorphism, GeneticGenotypeCDX2 Transcription Factor

Substanzen

Receptors, Calcitriol25-hydroxyvitamin DVitamin DVDR protein, humanCDX2 protein, humanCDX2 Transcription Factor

Autor:innen und Institutionen

  • Department of Nutrition, Guangdong Provincial Key Laboratory of Food, Nutrition, and Health, School of Public Health, Sun Yat-sen University, Guangzhou, China.
  • Department of Public Health, Guiyang Center for Disease Control and Prevention, Guiyang, China.
  • Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
  • Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
  • Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Yale University School of Nursing, Orange, CT, USA.

ORCID-Profile: Jing Shu, Tongtong He, Xuehong Zhang, Aiping Fang

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Guangdong Province
  • Science and Technology Program of Guangzhou

Zitieren

APA

Shu, J., Zhang, M., Dong, X., Long, J., Li, Y., Tan, P., He, T., Giovannucci, E. L., Zhang, X., Zhou, Z., Xu, Y., Xu, X., Peng, T., Lu, J., Chen, M., Zhu, H., Zhang, Y., & Fang, A. (2024). Vitamin D receptor gene polymorphisms, bioavailable 25-hydroxyvitamin D, and hepatocellular carcinoma survival. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djae116

Vancouver

Shu J, Zhang M, Dong X, Long J, Li Y, Tan P, et al. Vitamin D receptor gene polymorphisms, bioavailable 25-hydroxyvitamin D, and hepatocellular carcinoma survival. JNCI: Journal of the National Cancer Institute. 2024. doi:10.1093/jnci/djae116

BibTeX
@article{Shu2024,
  author = {Shu, Jing and Zhang, Mingjie and Dong, Xiaocong and Long, Jingan and Li, Yunshan and Tan, Peishan and He, Tongtong and Giovannucci, Edward L and Zhang, Xuehong and Zhou, Zhongguo and Xu, Yanjun and Xu, Xiaojun and Peng, Tianyou and Lu, Jialin and Chen, Minshan and Zhu, Huilian and Zhang, Yaojun and Fang, Aiping},
  title = {Vitamin D receptor gene polymorphisms, bioavailable 25-hydroxyvitamin D, and hepatocellular carcinoma survival},
  journal = {JNCI: Journal of the National Cancer Institute},
  year = {2024},
  doi = {10.1093/jnci/djae116}
}
Kostenlos starten →